evaluated by the Systemic Lupus Activity Measure (SLAM), 6 and the active disease was considered as the SLAM higher than 10. The active stage of SLE was reported in 6 patients, including 4 individuals treated with immunosuppressants (TAbLE 1) .
In all patients, high-resolution computed tomography (HRCT), spirometry, body plethysmography, and EBC and BALF collection were performed. Spirometry and EBC collection were performed in all healthy individuals, while BALF only in 20. Patients were divided into 2 groups based on the presence of pulmonary involvement on chest HRCT. The study was approved by the Ethics Committee of the Medical University of Lodz (RNN/146/07/KE).
PATIENTs ANd mEThOds
The study included 34 patients fulfilling the revised American College of Rheumatology criteria for the diagnosis of SLE, 5 and 31 healthy controls matched for sex and age. Sixteen patients were taking corticosteroids (prednisone, 5-20 mg/d; methylprednisolone, 4-24 mg/d); 3 of those patients received corticosteroids in combination with azathioprine (100-150 mg/d); 1 patient received mycophenolate mofetil (1000 mg/d). Twelve patients were on a maintenance dose of immunosuppressive drugs (prednisone, ≤10 mg/d; methylprednisolone, ≤ 8 mg/d; azathioprine, ≤100 mg/d). Patients with the previous history of pulmonary disorders other than SLE and with current infection were excluded. The disease activity was IL-6 was detected in all BALF samples and IL-10 in 32 BALF samples of patients with SLE. IL-6 was not detected in EBC samples, while IL-10 was detected in all EBC samples of patients with SLE. The mean IL-6 and IL-10 concentrations in the BALF and the IL-10 concentration in the EBC were higher in patients with SLE compared with controls (IL-6 BALF, 4.03 ±8.3 vs. 0.62 ±1.2 pg/ml, P <0.0001; IL-10 BALF, 5.54 ±1.85 vs. 0.00 ±1.82 pg/ml, P <0.0001; IL-10 EBC, 8.28 ±2.7 vs. 0.00±1.68 pg/ml, P <0.0001; respectively) (TAbLE 2).
The IL-10 level in the EBC was positively correlated with SLE activity (r = -0.40, P = 0.019),
HRCT was performed using a 64-Slice CT (GE Healthcare LightSpeed, United Kingdom) with 1.25 mm single slices, collimation at 1-centimeter intervals through the lungs, 120 kV, 265 mA, and 0.6-second scan time. The images were obtained at the window level of -700 Hounsfield units (HU) and the window width of 1500 HU, and examined independently by 2 ex perienced radiologists.
Spirometry was performed according to the European Respiratory Society (ERS) standards with the MES LUNGTEST 1000 model. 7 The forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV 1 ) were measured. The Tiffenau index (FEV 1 /FVC ratio) was calculated. Body plethysmography was performed according to the ERS standards 8 with a plethysmograph (Jaeger, Germany). The residual volume (RV) and the total lung capacity were measured.
The EBC was collected using a commercial condenser (Ecoscreen, Jaeger) following the available recommendations. 9 After rinsing their mouth with distilled water, patients were asked to breathe out spontaneously for 10 minutes through a mouthpiece, and the condensate was immediately frozen.
The BALF was collected during bronchoscopy using a flexible bronchoscope (Olympus B1-IT20; Olympus Optical, Japan) according to the British Thoracic Society guidelines.
10 The tip of the bronchoscope was wedged in the lingular segments, and 5 × 50 ml aliquots of sterile 0.9% NaCl solution at 37ºC were poured and recovered by gentle suction after each part. The fluid was collect ed, filtered through the gauze, and centrifuged. The pellet was suspended in a phosphate buffer. Cytospins were prepared and the slides were stained with the May -Grünwald Giemsa stain. The total cell count was calculated (n × 10 6 ) under the light microscope and the numbers of macrophages, lymphocytes, neutrophils, and eosinophils were presented as a percentage of the total cell count. The supernatants were immediately frozen. Bronchoscopy was always the final procedure.
All samples of the EBC and BALF were collected in the morning (8:00 and 10:00 a.m.) to avoid Data are presented as mean ± standard error of the mean (median) (25th percentile; 75th percentile)
Abbreviations: BALF -bronchoalveolar lavage fluid, EBC -exhaled breath condensate, IL-6 -interleukin 6, IL-10 -interleukin 10, NS -nonsignificant, TCC -total cell count of lymphocytes in BALF, FEV 1 , or FVC (data not shown). There were no differences between the levels of IL-6, IL-10 in BALF and EBC, BALF cell percentage, SLAM, FEV 1 , FVC, or total lung capacity in the groups with or without immunosuppressive treatment.
dIsCussION The pathogenesis of SLE is still only partly understood. In autoimmune diseases, the imbalance between proinflammatory and anti-inflammatory cytokines has been suggested to play an important role in its clinical and organ manifestation. Therefore, cytokines have become the subject of numerous studies to explain the pathomechanism of immune regulation in SLE. 11
The most frequent pulmonary involvement in patients with SLE were fibrotic changes (35% of the patients; TAbLE 1). The pulmonary changes related to interstitial abnormalities are observed on CT scans of 30% to 38% of the patients with SLE, even those with normal chest radiographs. 12 Our results confirmed the high prevalence of fibrotic changes in the lungs of SLE patients.
Our study has been the first to measure the concentrations of IL-6 and IL-10 in the EBC of patients with SLE. Al-Mutairi et al. 13 reported that proinflammatory cytokines (tumor necrosis factor, interferon-γ, IL-8) were more prevalent in the serum of patients with pulmonary involvement compared with those without pulmonary manifestations. However, the serum levels of IL-10 were similar in the pulmonary and nonpulmonary phenotypes.
13
The present study revealed increased IL-10 levels in the BALF and EBC of patients with SLE. Plasma IL-10 concentrations are higher in these patients compared with healthy individuals. 14 The increase is caused particularly by excessive IL-10 production by monocytes and a subset of B cells. 15 The peripheral blood mononuclear cells of patients with lupus spontaneously produce significantly more IL-10 than those in healthy people. 16 The disease severity correlates with elevated IL-10 concentrations. 17, 18 The serum levels the percentage of alveolar macrophages in BALF (r = 0.39, P = 0.02), FEV 1 (r = 0.43, P = 0.022), and FVC (r = 0.40, P = 0.035). It was negatively correlated with the percentage of lymphocytes in BALF (r = -0.43, P = 0.011). The IL-10 level in BALF showed a similar tendency to correlate with SLE activity as in EBC (r = -0.29, P = 0.09) (TAbLE 3) . There were no correlations between IL-6 levels and the SLAM or the results of lung function tests.
Patients with pulmonary involvement The SLAM was significantly higher and the total lung capacity was significantly lower in patients with pulmonary manifestation of SLE (8.00 ±3.17 vs. 6.00 ±2.31, P = 0.01; 88.00 ±28.29 vs. 112 ±21.08 % predicted, P = 0.01; respectively) (FIGuRE 1). There were no differences between patients with and without pulmonary manifestations in spirometric results and cytokine concentrations in the BALF and EBC (TAbLE 4). In patients with pulmonary involvement, the IL-10 level in the EBC correlated negatively with the duration of the disease (r = -0.61, P = 0.01) and the percentage of lymphocytes in the BALF (r = -0.5, P = 0.04). It correlated positively with FEV 1 (r = 0.55, P = 0.03) and FVC (r = 0.59, P = 0.02) (FIGuRE 2) . The SLAM correlated negatively with FEV 1 (r = -0.53, P = 0.035) and FVC (r = -0.67, P = 0.006) (TAbLE 5). In patients without pulmonary involvement, no correlations were found between the IL-10 level in the EBC and the duration of the disease, the percentage the disease correlated negatively with FEV 1 and FVC. It is possible that IL-10 protects against pulmonary manifestations of SLE but our findings need to be confirmed. The studies of healthy members of SLE multiplex families (families with more than 1 member with SLE) revealed higher plasma IL-10 concentrations compared with controls. 21 Treatment of SLE patients with murine anti-IL-10 monoclonal antibodies caused a clinical improvement, especially a reduction in cutaneous lesions, joint symptoms, and the SLEDAI score.
22 Increased IL-10 levels were shown to augment activation-induced apoptosis of SLE T cells and increase the burden of self-antigens. This effect is decreased by anti-IL-10 antibodies.
Both B cells and cytokines that affect B-cell survival and activation are considered the crucial factors in the pathogenesis of SLE. The effect of IL-6 is mainly proinflammatory: the activation of IL-10 have been found to positively correlate with anti-ds DNA antibody titers and the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) and negatively with complement C3 levels. 19, 20 However, in the present study, the IL-10 level in the EBC was found to correlate negatively with the activity of SLE, and it showed a similar tendency in the BALF. This finding could confirm that of Capper et al. 18 regarding the coexistence of groups of SLE patients with different patterns of cytokine activity. They found a group of patients with a completely different cytokine profile to that of other SLE patients; the differences could be due to varied etiologies of SLE.
Our study showed that in patients with SLE, the IL-10 level in the EBC correlated negatively with the SLAM and positively with FEV 1 and FVC. Additionally, in patients with pulmonary involvement, the IL-10 level in the EBC also correlated positively with FEV 1 and FVC, and the activity of 
25
Patients with SLE were observed to have an increased serum level of IL-6. Moreover, IL-6 concentration was associated with the severity of the disease. 26, 27 The present study revealed an increased IL-6 level in the BALF of patients with SLE, and the lack of correlation between the disease activity and the IL-6 level in the BALF. Previously, the IL-6 level was reported to correlate with hematologic disease activity in patients with SLE, and high IL-6 levels were found to be present in the urine of patients with active nephritis.
28 Additionally, neuropsychiatric manifestation has been associated with an increased IL-6 concentration in the cerebrospinal fluid of SLE patients.
29 An increased plasma level of IL-6 was implicated in the development of pulmonary manifestations such as pleural effusion, lupus pneumonitis, interstitial pneumonitis, and pulmonary hypertension.
30-32 Miyata et al. 33 observed that IL-6 caused pulmonary hypertension in rats. The reports of increased IL-6 levels in the local tissues have highlighted the importance of IL-6 in the pathogenesis of local inflammation. However, our results did not reveal similar correlations.
In conclusion, our study indicates that IL-6 and IL-10 play an important role in the pathogenesis of SLE. The data suggest that the IL-10 concentration in EBC may be a useful biomarker of disease activity in SLE and may have a prognostic value. It is likely that IL-10 has a protective role against pulmonary manifestations of SLE. Further studies are necessary to evaluate the prognostic role of these biomarkers in the EBC and BALF of SLE patients. 
